<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2007-08-29" updated="2020-01-02">
  <drugbank-id primary="true">DB01598</drugbank-id>
  <name>Imipenem</name>
  <description>Imipenem is a semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains.[label] It is stable to many beta-lactamases. Similar compounds include [meropenem], known for having greater activity against Gram negative bacteria, and the newer [ertapenem] which exhibits a longer half-life due to increased binding to plasma proteins.[A15389] Imipenem is commonly used in combination with [cilastatin] and is now available in a triple-drug product with cilastatin and [relebactam] which was recently approved by the FDA. Imipenem was first approved by the FDA in November 1985 as the combination product Primaxin marketed by Merck &amp; Co.[L7628]</description>
  <cas-number>64221-86-9</cas-number>
  <unii>Q20IM7HE75</unii>
  <average-mass>299.346</average-mass>
  <monoisotopic-mass>299.093976737</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A2527</ref-id>
        <pubmed-id>19076841</pubmed-id>
        <citation>Kattan JN, Villegas MV, Quinn JP: New developments in carbapenems. Clin Microbiol Infect. 2008 Dec;14(12):1102-11. doi: 10.1111/j.1469-0691.2008.02101.x.</citation>
      </article>
      <article>
        <ref-id>A2528</ref-id>
        <pubmed-id>3530614</pubmed-id>
        <citation>Pastel DA: Imipenem-cilastatin sodium, a broad-spectrum carbapenem antibiotic combination. Clin Pharm. 1986 Sep;5(9):719-36.</citation>
      </article>
      <article>
        <ref-id>A2530</ref-id>
        <pubmed-id>1382937</pubmed-id>
        <citation>Buckley MM, Brogden RN, Barradell LB, Goa KL: Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1992 Sep;44(3):408-44.</citation>
      </article>
      <article>
        <ref-id>A2531</ref-id>
        <pubmed-id>9573653</pubmed-id>
        <citation>Richerson MA, Ambrose PG, Quintiliani R, Nightingale CH: Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem. Conn Med. 1998 Mar;62(3):165-9.</citation>
      </article>
      <article>
        <ref-id>A2532</ref-id>
        <pubmed-id>3859213</pubmed-id>
        <citation>Birnbaum J, Kahan FM, Kropp H, MacDonald JS: Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am J Med. 1985 Jun 7;78(6A):3-21.</citation>
      </article>
      <article>
        <ref-id>A2533</ref-id>
        <pubmed-id>1921491</pubmed-id>
        <citation>Hellinger WC, Brewer NS: Imipenem. Mayo Clin Proc. 1991 Oct;66(10):1074-81.</citation>
      </article>
      <article>
        <ref-id>A2534</ref-id>
        <pubmed-id>6365872</pubmed-id>
        <citation>Kahan FM, Kropp H, Sundelof JG, Birnbaum J: Thienamycin: development of imipenen-cilastatin. J Antimicrob Chemother. 1983 Dec;12 Suppl D:1-35.</citation>
      </article>
      <article>
        <ref-id>A181271</ref-id>
        <pubmed-id>8741235</pubmed-id>
        <citation>Balfour JA, Bryson HM, Brogden RN: Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs. 1996 Jan;51(1):99-136. doi: 10.2165/00003495-199651010-00008.</citation>
      </article>
      <article>
        <ref-id>A15388</ref-id>
        <pubmed-id>18076336</pubmed-id>
        <citation>Nicolau DP: Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother. 2008 Jan;9(1):23-37.</citation>
      </article>
      <article>
        <ref-id>A15389</ref-id>
        <pubmed-id>17488146</pubmed-id>
        <citation>Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA: Comparative review of the carbapenems. Drugs. 2007;67(7):1027-52.</citation>
      </article>
    </articles>
    <textbooks>
      <textbook>
        <ref-id>T116</ref-id>
        <isbn>978-1-25-958473-2</isbn>
        <citation>Brunton LL, Hilal-Dandan R, Knollmann BC. eds (2018). Goodman &amp; Gilman's: The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill Education.</citation>
      </textbook>
    </textbooks>
    <links>
      <link>
        <ref-id>L7526</ref-id>
        <title>FDA: Primaxin Label</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050587s081lbl.pdf</url>
      </link>
      <link>
        <ref-id>L7568</ref-id>
        <title>FDA: Recarbrio Label</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf</url>
      </link>
      <link>
        <ref-id>L7628</ref-id>
        <title>Drugs@FDA: Primaxin</title>
        <url>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=050587</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference>Maurizio Zenoni, "Imipenem production process." U.S. Patent US20020095034, issued July 18, 2002.</synthesis-reference>
  <indication>Imipenem is indicated, in combination with [cilastatin] with or without [relebactam], for the treatment of bacterial infections including respiratory, skin, bone, gynecologic, urinary tract, and intra-abdominal as well as septicemia and endocarditis.[L7526,L7568]</indication>
  <pharmacodynamics>Imipenem is a beta-lactam antibiotic belongings to the subgroup of carbapenems.[L7526,L7568] Imipenem is active against aerobic and anaerobic Gram positive as well as Gram negative bacteria including &lt;i&gt;Pseudomonas aeruginosa&lt;/i&gt; and the &lt;i&gt;Enterococcus&lt;/i&gt;. It exerts a bactericidal effects by disrupting cell wall synthesis.</pharmacodynamics>
  <mechanism-of-action>Imipenem acts as an antimicrobial through the inhibition of cell wall synthesis of various gram-positive and gram-negative bacteria.[L7526,L7568] This inhibition of cell wall synthesis in gram-negative bateria is attained by binding to penicillin-binding proteins (PBPs). In E. coli and selected strains of P. aeruginosa, imipenem has shown to have the highest affinity to PBP-2, PBP-1a, and PBP-1b.[A15388] This inhibition of PBPs prevents the bacterial cell from adding to the peptidoglycan polymer which forms the bacterial cell wall eventually leading to cell death.[T116]</mechanism-of-action>
  <toxicity>In case of overdose with the combination product, including [relebactam] and [cilastatin], it is recommended to provide supportive care.[L7568] Imipenem, cilastatin, and relebactam may be removed via hemodialysis. </toxicity>
  <metabolism>Imipenem is metabolized by renal dehydropeptidase.[label,L7526]</metabolism>
  <absorption>Imipenem is not effectively absorbed from the gastrointestinal tract and therefore must be administered parenterally. The bioavailability of the IM injection is 89%. [A181271]</absorption>
  <half-life>When given via IV injection imipenem has a half-life of 1 h.[label,A2530,A181271] The apparent half-life of the IM injection ranges from 1.3-5.1 h, likely due to slower absorption form the injection site. </half-life>
  <protein-binding>Imipenem is 20% bound to plasma proteins. [label,L7526]</protein-binding>
  <route-of-elimination>Approximately 70% of imipenem is excreted in the urine as the parent drug.[label,L7526]</route-of-elimination>
  <volume-of-distribution>The reported volume of distribution for imipenem ranges from 0.23-0.31 L/kg.[label,A2530,A181271]</volume-of-distribution>
  <clearance>The total clearance of imipenem is 0.2 L/h/kg.[A181271] When used alone, the renal clearance is 0.05 L/h/kg. In combination with cilastatin the renal clearance of imipenem is 0.15 L/h/kg, likely due to the increased concentration of the parent drug.</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as thienamycins. These are beta-lactam antibiotics that differ from penicillins in having the thiazolidine sulfur atom replaced by carbon, the sulfur then becoming the first atom in the side chain.</description>
    <direct-parent>Thienamycins</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Lactams</class>
    <subclass>Beta lactams</subclass>
    <alternative-parent>Alpha amino acids and derivatives</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Azepines</alternative-parent>
    <alternative-parent>Azetidines</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboxamidines</alternative-parent>
    <alternative-parent>Carboximidamides</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Formamidines</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Imines</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Pyrroline carboxylic acids</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <alternative-parent>Sulfenyl compounds</alternative-parent>
    <alternative-parent>Tertiary carboxylic acid amides</alternative-parent>
    <alternative-parent>Thioenol ethers</alternative-parent>
    <alternative-parent>Vinylogous thioesters</alternative-parent>
    <substituent>Alcohol</substituent>
    <substituent>Aliphatic heteropolycyclic compound</substituent>
    <substituent>Alpha-amino acid or derivatives</substituent>
    <substituent>Amidine</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Azepine</substituent>
    <substituent>Azetidine</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboximidamide</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Carboxylic acid amidine</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Formamidine</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Imine</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Organosulfur compound</substituent>
    <substituent>Pyrroline</substituent>
    <substituent>Pyrroline carboxylic acid</substituent>
    <substituent>Pyrroline carboxylic acid or derivatives</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Sulfenyl compound</substituent>
    <substituent>Tertiary carboxylic acid amide</substituent>
    <substituent>Thienamycin</substituent>
    <substituent>Thioenolether</substituent>
    <substituent>Vinylogous thioester</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT002429</drugbank-id>
      <name>Imipenem monohydrate</name>
      <unii>71OTZ9ZE0A</unii>
      <cas-number>74431-23-5</cas-number>
      <inchikey>GSOSVVULSKVSLQ-JJVRHELESA-N</inchikey>
      <average-mass>317.36</average-mass>
      <monoisotopic-mass>317.104541898</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">(5R,6S)-3-((2-(Formimidoylamino)ethyl)thio)-6-((R)-1-hydroxyethyl)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid</synonym>
    <synonym language="english" coder="">(5R,6S)-3-(2-Formimidoylamino-ethylsulfanyl)-6-((R)-1-hydroxy-ethyl)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid</synonym>
    <synonym language="german" coder="">(5R,6S)-6-((R)-1-Hydroxyethyl)-3-(2-(iminomethylamino)ethylthio)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carbonsaeure</synonym>
    <synonym language="english" coder="inn/ban">Imipenem</synonym>
    <synonym language="english" coder="">Imipenem anhydrous</synonym>
    <synonym language="latin" coder="">Imipenemum</synonym>
    <synonym language="english" coder="">N-formimidoyl thienamycin</synonym>
    <synonym language="english" coder="">N-formimidoylthienamycin</synonym>
  </synonyms>
  <products>
    <product>
      <name>Imipenem</name>
      <labeller>Merck Sharp &amp; Dohme Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>69806-0093</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>1 kg/1kg</strength>
      <route>Not applicable</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Imipenem and Cilastatin</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-9389</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-03</started-marketing-on>
      <ended-marketing-on>2018-07-09</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>ANDA090577</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Imipenem and Cilastatin</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-3508</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>ANDA090825</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Imipenem and Cilastatin</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-3507</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>ANDA090825</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Imipenem and Cilastatin</name>
      <labeller>Fresenius Kabi USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63323-349</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>ANDA090577</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Imipenem and Cilastatin</name>
      <labeller>Fresenius Kabi USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63323-322</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>ANDA090577</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Imipenem and Cilastatin for Injection</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02357429</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Imipenem and Cilastatin for Injection</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02357437</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-02</started-marketing-on>
      <ended-marketing-on>2019-06-28</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Imipenem and Cilastatin for Injection USP</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02358336</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Imipenem and Cilastatin for Injection USP</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02358344</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Imipenem and Cilastatin for Injection, USP</name>
      <labeller>Methapharm, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02439840</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Imipenem and Cilastatin for Injection, USP</name>
      <labeller>Methapharm, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02439859</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Imipenem and Cilastatin for Injection, USP</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02441225</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Imipenem and Cilastatin for Injection, USP</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02441233</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Primaxin</name>
      <labeller>Merck &amp; Co., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0006-3583</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-02-22</started-marketing-on>
      <ended-marketing-on>2006-02-22</ended-marketing-on>
      <dosage-form>Injection, powder, for suspension</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Primaxin</name>
      <labeller>Merck &amp; Co., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0006-3517</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-01-26</started-marketing-on>
      <ended-marketing-on>2006-01-26</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Primaxin</name>
      <labeller>Merck &amp; Co., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0006-3666</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-01-26</started-marketing-on>
      <ended-marketing-on>2006-01-26</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Primaxin 250</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00717274</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on>2013-07-15</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Primaxin 500</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00717282</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Primaxin Im</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0006-3582</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-12-14</started-marketing-on>
      <ended-marketing-on>2011-04-30</ended-marketing-on>
      <dosage-form>Injection, powder, for suspension</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number>NDA050630</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Primaxin IV</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-5030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-11-26</started-marketing-on>
      <ended-marketing-on>2013-12-31</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA050587</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Primaxin IV</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-5019</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-01-08</started-marketing-on>
      <ended-marketing-on>2015-05-31</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>ANDA062756</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Primaxin IV</name>
      <labeller>Merck Sharp &amp; Dohme Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0006-3514</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-11-26</started-marketing-on>
      <ended-marketing-on>2017-05-01</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA050587</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Primaxin IV</name>
      <labeller>Merck Sharp &amp; Dohme Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0006-3516</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-11-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA050587</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Primaxin IV</name>
      <labeller>Merck Sharp &amp; Dohme Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0006-3551</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-01-08</started-marketing-on>
      <ended-marketing-on>2016-05-31</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>ANDA062756</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Primaxin IV</name>
      <labeller>Merck Sharp &amp; Dohme Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0006-3552</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-01-08</started-marketing-on>
      <ended-marketing-on>2016-05-31</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>ANDA062756</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Primaxin IV 250/250 Add-vantage Vial</name>
      <labeller>Merck Frosst Canada &amp; Cie, Merck Frosst Canada &amp; Co.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01911430</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>2000-04-05</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Primaxin IV 500</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01911449</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>2009-05-13</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-imipenem-cilastatin</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02351692</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ran-imipenem-cilastatin</name>
      <labeller>Ranbaxy Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02351706</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Tienamycin</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Imipenem and Cilastatin</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Primaxin Im</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Primaxin IV</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Primaxin IV</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Primaxin</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Primaxin</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Primaxin</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Imipenem and Cilastatin</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Imipenem and Cilastatin</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Imipenem</name>
      <ingredients>Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Imipenem and Cilastatin</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Imipenem and Cilastatin</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Primaxin IV</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Primaxin IV</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Primaxin IV</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Primaxin IV</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Primaxin 500</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Ran-imipenem-cilastatin</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Ran-imipenem-cilastatin</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Imipenem and Cilastatin for Injection USP</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Imipenem and Cilastatin for Injection USP</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Primaxin IV 500</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Primaxin IV 250/250 Add-vantage Vial</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Primaxin 250</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Imipenem and Cilastatin for Injection, USP</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Imipenem and Cilastatin for Injection, USP</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Imipenem and Cilastatin for Injection, USP</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Imipenem and Cilastatin for Injection, USP</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Imipenem and Cilastatin for Injection</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
    <mixture>
      <name>Imipenem and Cilastatin for Injection</name>
      <ingredients>Cilastatin + Imipenem</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Cardinal Health</name>
      <url>http://www.cardinal.com</url>
    </packager>
    <packager>
      <name>Merck &amp; Co.</name>
      <url>http://www.merck.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Agents that reduce seizure threshold</category>
      <mesh-id/>
    </category>
    <category>
      <category>Amides</category>
      <mesh-id>D000577</mesh-id>
    </category>
    <category>
      <category>Anti-Bacterial Agents</category>
      <mesh-id>D000900</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antibacterials for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antiinfectives for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Beta-Lactam Antibacterials</category>
      <mesh-id/>
    </category>
    <category>
      <category>beta-Lactams</category>
      <mesh-id>D047090</mesh-id>
    </category>
    <category>
      <category>Carbapenems</category>
      <mesh-id>D015780</mesh-id>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Lactams</category>
      <mesh-id>D007769</mesh-id>
    </category>
    <category>
      <category>Neurotoxic agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Penem Antibacterial</category>
      <mesh-id/>
    </category>
    <category>
      <category>Sulfur Compounds</category>
      <mesh-id>D013457</mesh-id>
    </category>
    <category>
      <category>Thienamycins</category>
      <mesh-id>D013845</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Pseudomonas aeruginosa</affected-organism>
    <affected-organism>Streptococcus agalactiae</affected-organism>
    <affected-organism>Haemophilus influenzae</affected-organism>
    <affected-organism>Escherichia coli</affected-organism>
    <affected-organism>Staphylococcus aureus</affected-organism>
    <affected-organism>Enterococcus faecalis</affected-organism>
    <affected-organism>Staphylococcus epidermidis</affected-organism>
    <affected-organism>Serratia marcescens</affected-organism>
    <affected-organism>Proteus vulgaris</affected-organism>
    <affected-organism>Providencia rettgeri</affected-organism>
    <affected-organism>Morganella morganii</affected-organism>
    <affected-organism>Enterobacter cloacae</affected-organism>
    <affected-organism>Klebsiella pneumoniae</affected-organism>
    <affected-organism>Haemophilus parainfluenzae</affected-organism>
    <affected-organism>Citrobacter freundii</affected-organism>
    <affected-organism>Bacteroides thetaiotaomicron</affected-organism>
    <affected-organism>Klebsiella aerogenes</affected-organism>
    <affected-organism>Bacteroides caccae</affected-organism>
    <affected-organism>Bacteroides ovatus</affected-organism>
    <affected-organism>Bacteroides stercoris</affected-organism>
    <affected-organism>Bacteroides uniformis</affected-organism>
    <affected-organism>Bacteroides vulgatus</affected-organism>
    <affected-organism>Fusobacterium nucleatum</affected-organism>
    <affected-organism>Parabacteroides distasonis</affected-organism>
    <affected-organism>Acinetobacter spp.</affected-organism>
    <affected-organism>Enterobacter spp.</affected-organism>
    <affected-organism>Klebsiella spp.</affected-organism>
    <affected-organism>Citrobacter spp.</affected-organism>
    <affected-organism>Proteus spp.</affected-organism>
    <affected-organism>Bifidobacterium spp.</affected-organism>
    <affected-organism>Clostridium spp.</affected-organism>
    <affected-organism>Eubacterium spp.</affected-organism>
    <affected-organism>Peptococcus spp.</affected-organism>
    <affected-organism>Peptostreptococcus spp.</affected-organism>
    <affected-organism>Propionibacterium spp.</affected-organism>
    <affected-organism>Bacteroides spp.</affected-organism>
    <affected-organism>Fusobacterium spp.</affected-organism>
    <affected-organism>Serratia spp.</affected-organism>
    <affected-organism>Gardnerella vaginalis</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Powder</form>
      <route>Not applicable</route>
      <strength>1 kg/1kg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, powder, for suspension</form>
      <route>Intramuscular</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="J01DH51">
      <level code="J01DH">Carbapenems</level>
      <level code="J01D">OTHER BETA-LACTAM ANTIBACTERIALS</level>
      <level code="J01">ANTIBACTERIALS FOR SYSTEMIC USE</level>
      <level code="J">ANTIINFECTIVES FOR SYSTEMIC USE</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB01598.pdf?1563836929</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB01598.pdf?1563996468</msds>
  <patents>
    <patent>
      <number>8487093</number>
      <country>United States</country>
      <approved>2013-07-16</approved>
      <expires>2029-11-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>Cyclosporine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01004</drugbank-id>
      <name>Ganciclovir</name>
      <description>The risk or severity of generalized seizure can be increased when Ganciclovir is combined with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01610</drugbank-id>
      <name>Valganciclovir</name>
      <description>The risk or severity of generalized seizure can be increased when Valganciclovir is combined with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01032</drugbank-id>
      <name>Probenecid</name>
      <description>The serum concentration of Imipenem can be increased when it is combined with Probenecid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>The therapeutic efficacy of Valproic acid can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14022</drugbank-id>
      <name>Typhoid vaccine</name>
      <description>The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The risk or severity of bleeding can be increased when Imipenem is combined with Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>The risk or severity of bleeding can be increased when Imipenem is combined with Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The risk or severity of bleeding can be increased when Imipenem is combined with Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The risk or severity of bleeding can be increased when Imipenem is combined with Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The risk or severity of bleeding can be increased when Imipenem is combined with Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>The risk or severity of bleeding can be increased when Imipenem is combined with 4-hydroxycoumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>The risk or severity of bleeding can be increased when Imipenem is combined with Coumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The risk or severity of bleeding can be increased when Imipenem is combined with (R)-warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>The risk or severity of bleeding can be increased when Imipenem is combined with Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The risk or severity of bleeding can be increased when Imipenem is combined with Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>The risk or severity of bleeding can be increased when Imipenem is combined with Clorindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>The risk or severity of bleeding can be increased when Imipenem is combined with Diphenadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>The risk or severity of bleeding can be increased when Imipenem is combined with Tioclomarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The risk or severity of bleeding can be increased when Imipenem is combined with (S)-Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00186</drugbank-id>
      <name>Lorazepam</name>
      <description>The therapeutic efficacy of Lorazepam can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>The therapeutic efficacy of Pregabalin can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>The therapeutic efficacy of Butalbital can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The therapeutic efficacy of Phenytoin can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00273</drugbank-id>
      <name>Topiramate</name>
      <description>The therapeutic efficacy of Topiramate can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>The therapeutic efficacy of Pentobarbital can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>The therapeutic efficacy of Trimethadione can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>The therapeutic efficacy of Clobazam can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>The therapeutic efficacy of Secobarbital can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00463</drugbank-id>
      <name>Metharbital</name>
      <description>The therapeutic efficacy of Metharbital can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00474</drugbank-id>
      <name>Methohexital</name>
      <description>The therapeutic efficacy of Methohexital can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>The therapeutic efficacy of Mephenytoin can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The therapeutic efficacy of Carbamazepine can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>The therapeutic efficacy of Thiopental can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00617</drugbank-id>
      <name>Paramethadione</name>
      <description>The therapeutic efficacy of Paramethadione can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00628</drugbank-id>
      <name>Clorazepic acid</name>
      <description>The therapeutic efficacy of Clorazepic acid can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>The therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The therapeutic efficacy of Tizanidine can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00740</drugbank-id>
      <name>Riluzole</name>
      <description>The therapeutic efficacy of Riluzole can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00754</drugbank-id>
      <name>Ethotoin</name>
      <description>The therapeutic efficacy of Ethotoin can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00776</drugbank-id>
      <name>Oxcarbazepine</name>
      <description>The therapeutic efficacy of Oxcarbazepine can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The therapeutic efficacy of Primidone can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00819</drugbank-id>
      <name>Acetazolamide</name>
      <description>The therapeutic efficacy of Acetazolamide can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>The therapeutic efficacy of Diazepam can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00832</drugbank-id>
      <name>Phensuximide</name>
      <description>The therapeutic efficacy of Phensuximide can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00837</drugbank-id>
      <name>Progabide</name>
      <description>The therapeutic efficacy of Progabide can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>The therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00906</drugbank-id>
      <name>Tiagabine</name>
      <description>The therapeutic efficacy of Tiagabine can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>The therapeutic efficacy of Zonisamide can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00949</drugbank-id>
      <name>Felbamate</name>
      <description>The therapeutic efficacy of Felbamate can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00962</drugbank-id>
      <name>Zaleplon</name>
      <description>The therapeutic efficacy of Zaleplon can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00996</drugbank-id>
      <name>Gabapentin</name>
      <description>The therapeutic efficacy of Gabapentin can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01068</drugbank-id>
      <name>Clonazepam</name>
      <description>The therapeutic efficacy of Clonazepam can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01080</drugbank-id>
      <name>Vigabatrin</name>
      <description>The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01121</drugbank-id>
      <name>Phenacemide</name>
      <description>The therapeutic efficacy of Phenacemide can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01154</drugbank-id>
      <name>Thiamylal</name>
      <description>The therapeutic efficacy of Thiamylal can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The therapeutic efficacy of Phenobarbital can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01202</drugbank-id>
      <name>Levetiracetam</name>
      <description>The therapeutic efficacy of Levetiracetam can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01215</drugbank-id>
      <name>Estazolam</name>
      <description>The therapeutic efficacy of Estazolam can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>The therapeutic efficacy of Amobarbital can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>The therapeutic efficacy of Hexobarbital can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>The therapeutic efficacy of Barbital can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01511</drugbank-id>
      <name>Delorazepam</name>
      <description>The therapeutic efficacy of Delorazepam can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01595</drugbank-id>
      <name>Nitrazepam</name>
      <description>The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02207</drugbank-id>
      <name>7-Nitroindazole</name>
      <description>The therapeutic efficacy of 7-Nitroindazole can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04165</drugbank-id>
      <name>Valpromide</name>
      <description>The therapeutic efficacy of Valpromide can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The therapeutic efficacy of Flunarizine can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04953</drugbank-id>
      <name>Ezogabine</name>
      <description>The therapeutic efficacy of Ezogabine can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>The therapeutic efficacy of Methsuximide can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05541</drugbank-id>
      <name>Brivaracetam</name>
      <description>The therapeutic efficacy of Brivaracetam can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06201</drugbank-id>
      <name>Rufinamide</name>
      <description>The therapeutic efficacy of Rufinamide can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06218</drugbank-id>
      <name>Lacosamide</name>
      <description>The therapeutic efficacy of Lacosamide can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06458</drugbank-id>
      <name>Remacemide</name>
      <description>The therapeutic efficacy of Remacemide can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06470</drugbank-id>
      <name>Clomethiazole</name>
      <description>The therapeutic efficacy of Clomethiazole can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06512</drugbank-id>
      <name>Deramciclane</name>
      <description>The therapeutic efficacy of Deramciclane can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06527</drugbank-id>
      <name>Tramiprosate</name>
      <description>The therapeutic efficacy of Tramiprosate can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06554</drugbank-id>
      <name>Gaboxadol</name>
      <description>The therapeutic efficacy of Gaboxadol can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08329</drugbank-id>
      <name>Sulthiame</name>
      <description>The therapeutic efficacy of Sulthiame can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08883</drugbank-id>
      <name>Perampanel</name>
      <description>The therapeutic efficacy of Perampanel can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09001</drugbank-id>
      <name>Barbexaclone</name>
      <description>The therapeutic efficacy of Barbexaclone can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09011</drugbank-id>
      <name>Beclamide</name>
      <description>The therapeutic efficacy of Beclamide can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09061</drugbank-id>
      <name>Cannabidiol</name>
      <description>The therapeutic efficacy of Cannabidiol can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09117</drugbank-id>
      <name>Paraldehyde</name>
      <description>The therapeutic efficacy of Paraldehyde can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>The therapeutic efficacy of Stiripentol can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09119</drugbank-id>
      <name>Eslicarbazepine acetate</name>
      <description>The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11400</drugbank-id>
      <name>Doramectin</name>
      <description>The therapeutic efficacy of Doramectin can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11549</drugbank-id>
      <name>Tiletamine</name>
      <description>The therapeutic efficacy of Tiletamine can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11859</drugbank-id>
      <name>Brexanolone</name>
      <description>The therapeutic efficacy of Brexanolone can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11868</drugbank-id>
      <name>Etiracetam</name>
      <description>The therapeutic efficacy of Etiracetam can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12131</drugbank-id>
      <name>Vinpocetine</name>
      <description>The therapeutic efficacy of Vinpocetine can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12338</drugbank-id>
      <name>Carisbamate</name>
      <description>The therapeutic efficacy of Carisbamate can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13362</drugbank-id>
      <name>Pheneturide</name>
      <description>The therapeutic efficacy of Pheneturide can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13396</drugbank-id>
      <name>Neocitrullamon</name>
      <description>The therapeutic efficacy of Neocitrullamon can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13437</drugbank-id>
      <name>Medazepam</name>
      <description>The therapeutic efficacy of Medazepam can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13455</drugbank-id>
      <name>Phenibut</name>
      <description>The therapeutic efficacy of Phenibut can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13799</drugbank-id>
      <name>Ethadione</name>
      <description>The therapeutic efficacy of Ethadione can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14050</drugbank-id>
      <name>Cannabidivarin</name>
      <description>The therapeutic efficacy of Cannabidivarin can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14575</drugbank-id>
      <name>Eslicarbazepine</name>
      <description>The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15203</drugbank-id>
      <name>JNJ-26489112</name>
      <description>The therapeutic efficacy of JNJ-26489112 can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06119</drugbank-id>
      <name>Cenobamate</name>
      <description>The therapeutic efficacy of Cenobamate can be decreased when used in combination with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11640</drugbank-id>
      <name>Amifampridine</name>
      <description>The risk or severity of seizure can be increased when Imipenem is combined with Amifampridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06637</drugbank-id>
      <name>Dalfampridine</name>
      <description>The risk or severity of seizure can be increased when Imipenem is combined with Dalfampridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01156</drugbank-id>
      <name>Bupropion</name>
      <description>The risk or severity of seizure can be increased when Bupropion is combined with Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00202</drugbank-id>
      <name>Succinylcholine</name>
      <description>Succinylcholine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>Reserpine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>Ziprasidone may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00260</drugbank-id>
      <name>Cycloserine</name>
      <description>Cycloserine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>Amitriptyline may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>Protriptyline may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>Vinorelbine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>Clozapine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00372</drugbank-id>
      <name>Thiethylperazine</name>
      <description>Thiethylperazine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00391</drugbank-id>
      <name>Sulpiride</name>
      <description>Sulpiride may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00408</drugbank-id>
      <name>Loxapine</name>
      <description>Loxapine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00409</drugbank-id>
      <name>Remoxipride</name>
      <description>Remoxipride may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>Promazine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00433</drugbank-id>
      <name>Prochlorperazine</name>
      <description>Prochlorperazine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00444</drugbank-id>
      <name>Teniposide</name>
      <description>Teniposide may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00450</drugbank-id>
      <name>Droperidol</name>
      <description>Droperidol may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>Imipramine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>Chlorpromazine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>Haloperidol may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>Triflupromazine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>Cyclophosphamide may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>Nortriptyline may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>Vincristine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>Amoxapine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00623</drugbank-id>
      <name>Fluphenazine</name>
      <description>Fluphenazine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00649</drugbank-id>
      <name>Stavudine</name>
      <description>Stavudine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>Thioridazine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00680</drugbank-id>
      <name>Moricizine</name>
      <description>Moricizine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>Trimipramine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>Risperidone may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>Trifluoperazine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>Perphenazine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>Flupentixol may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>Ethanol may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00900</drugbank-id>
      <name>Didanosine</name>
      <description>Didanosine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>Cyclobenzaprine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00933</drugbank-id>
      <name>Mesoridazine</name>
      <description>Mesoridazine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01063</drugbank-id>
      <name>Acetophenazine</name>
      <description>Acetophenazine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>Promethazine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>Pimozide may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>Doxepin may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>Desipramine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01190</drugbank-id>
      <name>Clindamycin</name>
      <description>Clindamycin may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>Tubocurarine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>Paclitaxel may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>Aripiprazole may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>Chlorprothixene may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>Clomipramine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01245</drugbank-id>
      <name>Decamethonium</name>
      <description>Decamethonium may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01246</drugbank-id>
      <name>Alimemazine</name>
      <description>Alimemazine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>Paliperidone may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01294</drugbank-id>
      <name>Bismuth subsalicylate</name>
      <description>Bismuth subsalicylate may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium cation</name>
      <description>Lithium cation may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>Methotrimeprazine may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01608</drugbank-id>
      <name>Periciazine</name>
      <description>Imipenem may increase the neurotoxic activities of Periciazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01614</drugbank-id>
      <name>Acepromazine</name>
      <description>Imipenem may increase the neurotoxic activities of Acepromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01615</drugbank-id>
      <name>Aceprometazine</name>
      <description>Imipenem may increase the neurotoxic activities of Aceprometazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01618</drugbank-id>
      <name>Molindone</name>
      <description>Imipenem may increase the neurotoxic activities of Molindone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01621</drugbank-id>
      <name>Pipotiazine</name>
      <description>Imipenem may increase the neurotoxic activities of Pipotiazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01622</drugbank-id>
      <name>Thioproperazine</name>
      <description>Imipenem may increase the neurotoxic activities of Thioproperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01623</drugbank-id>
      <name>Thiothixene</name>
      <description>Imipenem may increase the neurotoxic activities of Thiothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>Imipenem may increase the neurotoxic activities of Zuclopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01627</drugbank-id>
      <name>Lincomycin</name>
      <description>Imipenem may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>Imipenem may increase the neurotoxic activities of Amineptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>Imipenem may increase the neurotoxic activities of Fluspirilene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04872</drugbank-id>
      <name>Osanetant</name>
      <description>Imipenem may increase the neurotoxic activities of Osanetant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04888</drugbank-id>
      <name>Bifeprunox</name>
      <description>Imipenem may increase the neurotoxic activities of Bifeprunox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>Imipenem may increase the neurotoxic activities of Iloperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05316</drugbank-id>
      <name>Pimavanserin</name>
      <description>Imipenem may increase the neurotoxic activities of Pimavanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05687</drugbank-id>
      <name>BL-1020</name>
      <description>Imipenem may increase the neurotoxic activities of BL-1020.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06016</drugbank-id>
      <name>Cariprazine</name>
      <description>Imipenem may increase the neurotoxic activities of Cariprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06144</drugbank-id>
      <name>Sertindole</name>
      <description>Imipenem may increase the neurotoxic activities of Sertindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>Imipenem may increase the neurotoxic activities of Asenapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06288</drugbank-id>
      <name>Amisulpride</name>
      <description>Imipenem may increase the neurotoxic activities of Amisulpride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>Imipenem may increase the neurotoxic activities of Lurasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08922</drugbank-id>
      <name>Perospirone</name>
      <description>Imipenem may increase the neurotoxic activities of Perospirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08927</drugbank-id>
      <name>Amperozide</name>
      <description>Imipenem may increase the neurotoxic activities of Amperozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>Imipenem may increase the neurotoxic activities of Dimetacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09000</drugbank-id>
      <name>Cyamemazine</name>
      <description>Imipenem may increase the neurotoxic activities of Cyamemazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09016</drugbank-id>
      <name>Butriptyline</name>
      <description>Imipenem may increase the neurotoxic activities of Butriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>Imipenem may increase the neurotoxic activities of Brexpiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09154</drugbank-id>
      <name>Sodium citrate</name>
      <description>Imipenem may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>Imipenem may increase the neurotoxic activities of Dosulepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09223</drugbank-id>
      <name>Blonanserin</name>
      <description>Imipenem may increase the neurotoxic activities of Blonanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09224</drugbank-id>
      <name>Melperone</name>
      <description>Imipenem may increase the neurotoxic activities of Melperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09225</drugbank-id>
      <name>Zotepine</name>
      <description>Imipenem may increase the neurotoxic activities of Zotepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09226</drugbank-id>
      <name>RP-5063</name>
      <description>Imipenem may increase the neurotoxic activities of RP-5063.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>Imipenem may increase the neurotoxic activities of Methylene blue.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09275</drugbank-id>
      <name>Bismuth subcitrate potassium</name>
      <description>Imipenem may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09286</drugbank-id>
      <name>Pipamperone</name>
      <description>Imipenem may increase the neurotoxic activities of Pipamperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>Imipenem may increase the neurotoxic activities of Tianeptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09307</drugbank-id>
      <name>Oxaprotiline</name>
      <description>Imipenem may increase the neurotoxic activities of Oxaprotiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11281</drugbank-id>
      <name>Bismuth subcarbonate</name>
      <description>Imipenem may increase the neurotoxic activities of Bismuth subcarbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11376</drugbank-id>
      <name>Azaperone</name>
      <description>Imipenem may increase the neurotoxic activities of Azaperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11537</drugbank-id>
      <name>Pirlimycin</name>
      <description>Imipenem may increase the neurotoxic activities of Pirlimycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11540</drugbank-id>
      <name>Propiopromazine</name>
      <description>Imipenem may increase the neurotoxic activities of Propiopromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>Imipenem may increase the neurotoxic activities of Tetrahydropalmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12273</drugbank-id>
      <name>Ecopipam</name>
      <description>Imipenem may increase the neurotoxic activities of Ecopipam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12401</drugbank-id>
      <name>Bromperidol</name>
      <description>Imipenem may increase the neurotoxic activities of Bromperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12518</drugbank-id>
      <name>Raclopride</name>
      <description>Imipenem may increase the neurotoxic activities of Raclopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12693</drugbank-id>
      <name>Ritanserin</name>
      <description>Imipenem may increase the neurotoxic activities of Ritanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12710</drugbank-id>
      <name>Perazine</name>
      <description>Imipenem may increase the neurotoxic activities of Perazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12867</drugbank-id>
      <name>Benperidol</name>
      <description>Imipenem may increase the neurotoxic activities of Benperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>Imipenem may increase the neurotoxic activities of Opipramol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12958</drugbank-id>
      <name>Prothipendyl</name>
      <description>Imipenem may increase the neurotoxic activities of Prothipendyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13025</drugbank-id>
      <name>Tiapride</name>
      <description>Imipenem may increase the neurotoxic activities of Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13114</drugbank-id>
      <name>Amitriptylinoxide</name>
      <description>Imipenem may increase the neurotoxic activities of Amitriptylinoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13209</drugbank-id>
      <name>Bismuth subnitrate</name>
      <description>Imipenem may increase the neurotoxic activities of Bismuth subnitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13213</drugbank-id>
      <name>Butaperazine</name>
      <description>Imipenem may increase the neurotoxic activities of Butaperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13225</drugbank-id>
      <name>Dibenzepin</name>
      <description>Imipenem may increase the neurotoxic activities of Dibenzepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13246</drugbank-id>
      <name>Quinupramine</name>
      <description>Imipenem may increase the neurotoxic activities of Quinupramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13256</drugbank-id>
      <name>Clothiapine</name>
      <description>Imipenem may increase the neurotoxic activities of Clothiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13273</drugbank-id>
      <name>Sultopride</name>
      <description>Imipenem may increase the neurotoxic activities of Sultopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13382</drugbank-id>
      <name>Chlorproethazine</name>
      <description>Imipenem may increase the neurotoxic activities of Chlorproethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13384</drugbank-id>
      <name>Melitracen</name>
      <description>Imipenem may increase the neurotoxic activities of Melitracen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13403</drugbank-id>
      <name>Oxypertine</name>
      <description>Imipenem may increase the neurotoxic activities of Oxypertine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13411</drugbank-id>
      <name>Lofepramine</name>
      <description>Imipenem may increase the neurotoxic activities of Lofepramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13420</drugbank-id>
      <name>Thiazinam</name>
      <description>Imipenem may increase the neurotoxic activities of Thiazinam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13496</drugbank-id>
      <name>Iprindole</name>
      <description>Imipenem may increase the neurotoxic activities of Iprindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13523</drugbank-id>
      <name>Veralipride</name>
      <description>Imipenem may increase the neurotoxic activities of Veralipride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13552</drugbank-id>
      <name>Trifluperidol</name>
      <description>Imipenem may increase the neurotoxic activities of Trifluperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13554</drugbank-id>
      <name>Moperone</name>
      <description>Imipenem may increase the neurotoxic activities of Moperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13557</drugbank-id>
      <name>Thiopropazate</name>
      <description>Imipenem may increase the neurotoxic activities of Thiopropazate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13584</drugbank-id>
      <name>Gallamine</name>
      <description>Imipenem may increase the neurotoxic activities of Gallamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13598</drugbank-id>
      <name>Diethyl ether</name>
      <description>Imipenem may increase the neurotoxic activities of Diethyl ether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13665</drugbank-id>
      <name>Fluanisone</name>
      <description>Imipenem may increase the neurotoxic activities of Fluanisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13676</drugbank-id>
      <name>Mosapramine</name>
      <description>Imipenem may increase the neurotoxic activities of Mosapramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13782</drugbank-id>
      <name>Imipramine oxide</name>
      <description>Imipenem may increase the neurotoxic activities of Imipramine oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13784</drugbank-id>
      <name>Dixyrazine</name>
      <description>Imipenem may increase the neurotoxic activities of Dixyrazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13791</drugbank-id>
      <name>Penfluridol</name>
      <description>Imipenem may increase the neurotoxic activities of Penfluridol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13841</drugbank-id>
      <name>Clopenthixol</name>
      <description>Imipenem may increase the neurotoxic activities of Clopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13909</drugbank-id>
      <name>Bismuth subgallate</name>
      <description>Imipenem may increase the neurotoxic activities of Bismuth subgallate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13910</drugbank-id>
      <name>Valproate bismuth</name>
      <description>Imipenem may increase the neurotoxic activities of Valproate bismuth.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14185</drugbank-id>
      <name>Aripiprazole lauroxil</name>
      <description>Imipenem may increase the neurotoxic activities of Aripiprazole lauroxil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14651</drugbank-id>
      <name>Perphenazine enanthate</name>
      <description>Imipenem may increase the neurotoxic activities of Perphenazine enanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00781</drugbank-id>
      <name>Polymyxin B</name>
      <description>Imipenem may increase the neurotoxic activities of Polymyxin B.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-0.19</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-2.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>7.76e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-3.9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(5R,6S)-3-({2-[(E)-(aminomethylidene)amino]ethyl}sulfanyl)-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>zienam</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>299.346</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>299.093976737</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[H][C@]12CC(SCC\N=C\N)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C12H17N3O4S</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C12H17N3O4S/c1-6(16)9-7-4-8(20-3-2-14-5-13)10(12(18)19)15(7)11(9)17/h5-7,9,16H,2-4H2,1H3,(H2,13,14)(H,18,19)/t6-,7-,9-/m1/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>ZSKVGTPCRGIANV-ZXFLCMHBSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>116.22</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>75.84</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>31.1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>3.63</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>10.88</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>1E+004 mg/L</value>
      <source>MERCK INDEX (1996)</source>
    </property>
    <property>
      <kind>pKa</kind>
      <value>3.2</value>
      <source>MERCK INDEX (1996)</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>1390</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>471744</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>104838</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46505744</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C06665</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>94631</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50049708</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA449968</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000459</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Imipenem</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL148</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0003579</id>
      <name>Penicillin-binding protein 2</name>
      <organism>Escherichia coli (strain K12)</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15388</ref-id>
            <pubmed-id>18076336</pubmed-id>
            <citation>Nicolau DP: Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother. 2008 Jan;9(1):23-37.</citation>
          </article>
          <article>
            <ref-id>A15389</ref-id>
            <pubmed-id>17488146</pubmed-id>
            <citation>Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA: Comparative review of the carbapenems. Drugs. 2007;67(7):1027-52.</citation>
          </article>
          <article>
            <ref-id>A12844</ref-id>
            <pubmed-id>3873871</pubmed-id>
            <citation>Neu HC: Carbapenems: special properties contributing to their activity. Am J Med. 1985 Jun 7;78(6A):33-40.</citation>
          </article>
          <article>
            <ref-id>A15390</ref-id>
            <pubmed-id>11061029</pubmed-id>
            <citation>Luchi M, Morrison DC, Opal S, Yoneda K, Slotman G, Chambers H, Wiesenfeld H, Lemke J, Ryan JL, Horn D: A comparative trial of imipenem versus ceftazidime in the release of endotoxin and cytokine generation in patients with gram-negative urosepsis. Urosepsis Study Group. J Endotoxin Res. 2000;6(1):25-31.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L7568</ref-id>
            <title>FDA: Recarbrio Label</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P0AD65" source="Swiss-Prot">
        <name>Penicillin-binding protein 2</name>
        <general-function>Serine-type d-ala-d-ala carboxypeptidase activity</general-function>
        <specific-function>Cell wall formation; PBP-2 is responsible for the determination of the rod shape of the cell. It synthesizes cross-linked peptidoglycan from lipid intermediates.</specific-function>
        <gene-name>mrdA</gene-name>
        <locus/>
        <cellular-location>Cell inner membrane</cellular-location>
        <transmembrane-regions>22-42</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.16</theoretical-pi>
        <molecular-weight>70856.1</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="83333">Escherichia coli (strain K12)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X04516</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>42314</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P0AD65</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PBP2_ECOLI</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>PBP-2</synonym>
          <synonym>pbpA</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0017144|Penicillin-binding protein 2
MKLQNSFRDYTAESALFVRRALVAFLGILLLTGVLIANLYNLQIVRFTDYQTRSNENRIK
LVPIAPSRGIIYDRNGIPLALNRTIYQIEMMPEKVDNVQQTLDALRSVVDLTDDDIAAFR
KERARSHRFTSIPVKTNLTEVQVARFAVNQYRFPGVEVKGYKRRYYPYGSALTHVIGYVS
KINDKDVERLNNDGKLANYAATHDIGKLGIERYYEDVLHGQTGYEEVEVNNRGRVIRQLK
EVPPQAGHDIYLTLDLKLQQYIETLLAGSRAAVVVTDPRTGGVLALVSTPSYDPNLFVDG
ISSKDYSALLNDPNTPLVNRATQGVYPPASTVKPYVAVSALSAGVITRNTTLFDPGWWQL
PGSEKRYRDWKKWGHGRLNVTRSLEESADTFFYQVAYDMGIDRLSEWMGKFGYGHYTGID
LAEERSGNMPTREWKQKRFKKPWYQGDTIPVGIGQGYWTATPIQMSKALMILINDGIVKV
PHLLMSTAEDGKQVPWVQPHEPPVGDIHSGYWELAKDGMYGVANRPNGTAHKYFASAPYK
IAAKSGTAQVFGLKANETYNAHKIAERLRDHKLMTAFAPYNNPQVAVAMILENGGAGPAV
GTLMRQILDHIMLGDNNTDLPAENPAVAAAEDH</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017145|Penicillin-binding protein 2 (mrdA)
ATGAAACTACAGAACTCTTTTCGCGACTATACGGCAGAGTCCGCGCTGTTTGTGCGCCGG
GCGCTGGTCGCCTTTTTGGGGATTTTGCTGCTGACCGGCGTGCTTATCGCCAACCTGTAT
AATCTGCAAATTGTTCGCTTTACCGACTACCAGACCCGCTCTAATGAAAACCGCATTAAG
CTGGTGCCTATCGCGCCCAGCCGCGGCATTATCTACGATCGTAACGGTATCCCTCTGGCC
CTCAACCGCACTATCTACCAGATAGAAATGATGCCGGAGAAAGTCGATAACGTGCAGCAA
ACGCTGGACGCTTTGCGCAGCGTGGTAGATCTGACCGATGACGATATTGCTGCATTCCGA
AAAGAGCGCGCACGTTCACACCGTTTCACCTCTATTCCGGTGAAAACTAACCTGACCGAA
GTACAAGTAGCTCGCTTTGCCGTCAATCAGTACCGTTTTCCGGGTGTCGAAGTTAAAGGC
TATAAACGTCGTTACTATCCTTACGGTTCGGCGTTGACCCACGTCATCGGCTATGTGTCG
AAAATCAACGATAAAGACGTCGAACGCCTGAATAATGACGGCAAACTGGCCAACTATGCG
GCAACGCATGATATCGGTAAGCTGGGCATTGAGCGTTACTATGAAGATGTGCTGCACGGT
CAGACCGGTTATGAAGAGGTTGAAGTTAACAACCGTGGGCGTGTTATTCGCCAGTTAAAA
GAAGTACCACCGCAAGCCGGACACGATATTTACCTGACGCTGGATCTCAAACTCCAGCAA
TATATTGAAACGCTGCTGGCGGGTAGCCGCGCAGCTGTGGTAGTCACCGATCCGCGTACA
GGTGGGGTGCTGGCGCTGGTTTCCACGCCTAGTTATGACCCAAACTTGTTTGTTGACGGT
ATCTCCAGCAAAGATTATTCCGCCTTGTTGAACGATCCGAATACACCGCTGGTGAACCGC
GCCACACAGGGGGTTTATCCTCCCGCGTCTACAGTTAAACCCTATGTGGCGGTTTCGGCA
TTGAGCGCCGGGGTGATCACGCGCAATACGACGCTGTTTGACCCAGGCTGGTGGCAACTG
CCAGGTTCGGAAAAACGTTATCGTGACTGGAAAAAATGGGGCCACGGGCGTCTGAATGTC
ACAAGATCGCTGGAAGAATCTGCGGATACCTTCTTCTATCAGGTGGCCTACGATATGGGG
ATCGATCGCCTCTCCGAATGGATGGGTAAATTCGGTTATGGTCATTACACCGGTATCGAC
CTGGCGGAAGAACGTTCCGGCAACATGCCTACCCGCGAATGGAAACAGAAACGCTTTAAA
AAACCGTGGTATCAGGGTGACACCATTCCGGTTGGTATCGGTCAGGGTTACTGGACAGCG
ACCCCAATCCAGATGAGTAAGGCACTGATGATCCTGATTAATGACGGTATCGTGAAGGTT
CCTCATTTGCTGATGAGCACCGCCGAAGACGGCAAACAGGTGCCATGGGTACAGCCGCAT
GAACCGCCCGTCGGCGATATTCATTCCGGTTACTGGGAGCTGGCGAAAGACGGTATGTAC
GGTGTTGCTAACCGCCCTAACGGTACGGCGCATAAATACTTTGCTAGCGCACCGTACAAA
ATTGCGGCGAAATCCGGTACCGCTCAGGTCTTCGGTCTGAAAGCGAACGAAACCTATAAT
GCGCACAAAATTGCCGAGCGTTTACGTGACCACAAACTGATGACCGCCTTTGCGCCATAC
AACAATCCGCAAGTGGCTGTCGCCATGATTCTGGAGAACGGTGGTGCGGGTCCGGCGGTT
GGTACACTGATGCGCCAGATCCTCGACCACATTATGCTGGGTGATAACAACACCGATCTG
CCTGCGGAAAATCCAGCGGTTGCCGCAGCGGAGGACCATTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF03717</identifier>
            <name>PBP_dimer</name>
          </pfam>
          <pfam>
            <identifier>PF00905</identifier>
            <name>Transpeptidase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>penicillin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptidoglycan L,D-transpeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type D-Ala-D-Ala carboxypeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell wall organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidoglycan biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell shape</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0000488</id>
      <name>Penicillin-binding protein 1B</name>
      <organism>Escherichia coli (strain K12)</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15388</ref-id>
            <pubmed-id>18076336</pubmed-id>
            <citation>Nicolau DP: Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother. 2008 Jan;9(1):23-37.</citation>
          </article>
          <article>
            <ref-id>A15389</ref-id>
            <pubmed-id>17488146</pubmed-id>
            <citation>Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA: Comparative review of the carbapenems. Drugs. 2007;67(7):1027-52.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L7568</ref-id>
            <title>FDA: Recarbrio Label</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P02919" source="Swiss-Prot">
        <name>Penicillin-binding protein 1B</name>
        <general-function>Serine-type d-ala-d-ala carboxypeptidase activity</general-function>
        <specific-function>Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a penicillin-sensitive transpeptidase C-terminal domain (cross-linking of the peptide subunits).</specific-function>
        <gene-name>mrcB</gene-name>
        <locus/>
        <cellular-location>Cell inner membrane</cellular-location>
        <transmembrane-regions>64-87</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.46</theoretical-pi>
        <molecular-weight>94291.875</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="83333">Escherichia coli (strain K12)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X02163</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>42468</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P02919</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PBPB_ECOLI</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Murein polymerase</synonym>
          <synonym>PBP-1b</synonym>
          <synonym>pbpF</synonym>
          <synonym>ponB</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000974|Penicillin-binding protein 1B
MAGNDREPIGRKGKPTRPVKQKVSRRRYEDDDDYDDYDDYEDEEPMPRKGKGKGKGRKPR
GKRGWLWLLLKLAIVFAVLIAIYGVYLDQKIRSRIDGKVWQLPAAVYGRMVNLEPDMTIS
KNEMVKLLEATQYRQVSKMTRPGEFTVQANSIEMIRRPFDFPDSKEGQVRARLTFDGDHL
ATIVNMENNRQFGFFRLDPRLITMISSPNGEQRLFVPRSGFPDLLVDTLLATEDRHFYEH
DGISLYSIGRAVLANLTAGRTVQGASTLTQQLVKNLFLSSERSYWRKANEAYMALIMDAR
YSKDRILELYMNEVYLGQSGDNEIRGFPLASLYYFGRPVEELSLDQQALLVGMVKGASIY
NPWRNPKLALERRNLVLRLLQQQQIIDQELYDMLSARPLGVQPRGGVISPQPAFMQLVRQ
ELQAKLGDKVKDLSGVKIFTTFDSVAQDAAEKAAVEGIPALKKQRKLSDLETAIVVVDRF
SGEVRAMVGGSEPQFAGYNRAMQARRSIGSLAKPATYLTALSQPKIYRLNTWIADAPIAL
RQPNGQVWSPQNDDRRYSESGRVMLVDALTRSMNVPTVNLGMALGLPAVTETWIKLGVPK
DQLHPVPAMLLGALNLTPIEVAQAFQTIASGGNRAPLSALRSVIAEDGKVLYQSFPQAER
AVPAQAAYLTLWTMQQVVQRGTGRQLGAKYPNLHLAGKTGTTNNNVDTWFAGIDGSTVTI
TWVGRDNNQPTKLYGASGAMSIYQRYLANQTPTPLNLVPPEDIADMGVDYDGNFVCSGGM
RILPVWTSDPQSLCQQSEMQQQPSGNPFDQSSQPQQQPQQQPAQQEQKDSDGVAGWIKDM
FGSN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0018961|Penicillin-binding protein 1B (mrcB)
ATGGCCGGGAATGACCGCGAGCCAATTGGACGCAAAGGGAAACCGACGCGTCCGGTCAAA
CAAAAGGTAAGCCGTCGTCGTTACGAAGATGACGATGATTACGACGATTATGATGACTAT
GAGGATGAAGAACCGATGCCGCGCAAAGGTAAGGGCAAAGGCAAAGGGCGTAAGCCTCGT
GGCAAACGCGGCTGGCTATGGCTACTGCTAAAACTGGCTATCGTTTTTGCCGTGCTGATC
GCCATTTACGGCGTTTATCTCGATCAAAAAATTCGTAGCCGTATTGATGGCAAGGTCTGG
CAACTGCCTGCGGCAGTTTATGGCCGAATGGTCAATCTTGAGCCAGACATGACCATCAGC
AAGAACGAGATGGTGAAGCTGCTGGAGGCGACCCAGTATCGTCAGGTGTCGAAAATGACC
CGTCCTGGCGAATTTACCGTGCAGGCCAACAGCATTGAGATGATTCGCCGTCCGTTTGAT
TTCCCGGACAGTAAAGAAGGACAGGTGCGCGCGCGTCTGACCTTTGATGGCGATCATCTG
GCGACGATCGTCAATATGGAGAACAACCGTCAGTTCGGTTTCTTCCGTCTTGATCCGCGT
CTGATCACCATGATCTCTTCGCCAAACGGTGAGCAGCGTCTGTTTGTGCCGCGCAGTGGT
TTCCCGGATTTGCTGGTGGATACTTTGCTGGCGACAGAAGACCGTCATTTTTACGAGCAT
GATGGAATCAGTCTCTACTCAATCGGACGTGCGGTGCTGGCAAACCTGACCGCCGGACGC
ACGGTACAGGGTGCGAGTACGCTGACGCAACAGCTGGTGAAAAACCTGTTCCTCTCCAGC
GAGCGTTCTTACTGGCGTAAAGCGAACGAAGCTTACATGGCGCTGATCATGGACGCGCGT
TACAGCAAAGACCGTATTCTTGAGCTGTATATGAACGAGGTGTATCTCGGTCAGAGCGGC
GACAACGAAATCCGCGGCTTCCCGCTGGCAAGCTTGTATTACTTTGGTCGCCCGGTAGAA
GAGCTAAGCCTCGACCAGCAGGCGCTGTTAGTCGGTATGGTGAAAGGGGCGTCCATCTAC
AACCCGTGGCGTAACCCAAAACTGGCGCTGGAGCGACGTAATCTGGTGCTGCGTCTGCTG
CAACAGCAACAGATTATTGATCAAGAACTCTATGACATGTTGAGTGCCCGTCCGCTGGGG
GTTCAGCCGCGCGGTGGGGTGATCTCTCCTCAGCCAGCCTTTATGCAACTGGTGCGTCAG
GAGCTGCAGGCAAAACTGGGCGATAAGGTAAAAGATCTCTCCGGCGTGAAGATCTTCACT
ACCTTTGACTCGGTGGCCCAGGACGCGGCAGAAAAAGCCGCCGTGGAAGGCATTCCGGCA
CTGAAGAAACAGCGTAAGTTGAGCGATCTTGAAACTGCGATTGTGGTCGTCGACCGCTTT
AGTGGTGAAGTTCGTGCGATGGTCGGAGGTTCTGAGCCGCAGTTTGCGGGCTACAACCGT
GCGATGCAGGCGCGTCGTTCGATTGGTTCCCTTGCAAAACCAGCGACTTATCTGACGGCC
TTAAGCCAGCCGAAAATCTATCGTCTGAATACGTGGATTGCGGATGCGCCAATTGCGCTG
CGTCAGCCGAATGGCCAGGTCTGGTCACCGCAGAATGATGACCGTCGTTATAGCGAAAGC
GGCAGAGTGATGCTGGTGGATGCGTTGACCCGTTCGATGAACGTGCCGACGGTAAATCTG
GGGATGGCGCTGGGGCTGCCTGCGGTTACGGAGACCTGGATTAAACTGGGCGTACCGAAA
GATCAGTTGCATCCGGTTCCGGCAATGCTGCTGGGGGCGTTGAACTTAACGCCAATCGAA
GTGGCGCAGGCATTCCAGACCATCGCCAGCGGTGGTAACCGTGCACCGCTTTCTGCGCTG
CGTTCGGTAATCGCGGAAGATGGCAAAGTGCTGTATCAGAGCTTCCCGCAGGCGGAACGC
GCTGTTCCGGCGCAGGCGGCGTATCTGACACTATGGACCATGCAGCAGGTGGTACAACGC
GGTACGGGTCGTCAGCTTGGGGCGAAATACCCGAACCTGCATCTGGCAGGGAAAACAGGG
ACTACCAACAATAACGTAGATACCTGGTTTGCGGGCATTGACGGCAGCACGGTGACCATC
ACCTGGGTCGGCCGTGATAACAACCAGCCGACCAAACTGTATGGTGCCAGCGGGGCAATG
TCGATTTATCAGCGTTATCTGGCTAACCAGACGCCAACGCCGCTGAATCTTGTTCCGCCA
GAAGATATTGCAGATATGGGCGTGGACTACGACGGCAACTTTGTTTGCAGCGGTGGCATG
CGTATCTTGCCGGTCTGGACCAGCGATCCGCAATCGCTGTGCCAGCAGAGCGAGATGCAG
CAGCAGCCGTCAGGCAATCCGTTTGATCAGTCTTCTCAGCCGCAGCAACAGCCGCAACAG
CAACCTGCTCAGCAAGAGCAGAAAGACAGCGACGGTGTAGCCGGTTGGATCAAGGATATG
TTTGGTAGTAATTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00905</identifier>
            <name>Transpeptidase</name>
          </pfam>
          <pfam>
            <identifier>PF00912</identifier>
            <name>Transgly</name>
          </pfam>
          <pfam>
            <identifier>PF14814</identifier>
            <name>UB2H</name>
          </pfam>
          <pfam>
            <identifier>PF14812</identifier>
            <name>PBP1_TM</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of external side of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>peptidoglycan-based cell wall</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>penicillin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptidoglycan glycosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type D-Ala-D-Ala carboxypeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell wall organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidoglycan biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell shape</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="3">
      <id>BE0000588</id>
      <name>Penicillin-binding protein 1A</name>
      <organism>Escherichia coli (strain K12)</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15388</ref-id>
            <pubmed-id>18076336</pubmed-id>
            <citation>Nicolau DP: Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother. 2008 Jan;9(1):23-37.</citation>
          </article>
          <article>
            <ref-id>A15389</ref-id>
            <pubmed-id>17488146</pubmed-id>
            <citation>Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA: Comparative review of the carbapenems. Drugs. 2007;67(7):1027-52.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L7568</ref-id>
            <title>FDA: Recarbrio Label</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P02918" source="Swiss-Prot">
        <name>Penicillin-binding protein 1A</name>
        <general-function>Serine-type d-ala-d-ala carboxypeptidase activity</general-function>
        <specific-function>Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a penicillin-sensitive transpeptidase C-terminal domain (cross-linking of the peptide subunits).</specific-function>
        <gene-name>mrcA</gene-name>
        <locus/>
        <cellular-location>Cell inner membrane</cellular-location>
        <transmembrane-regions>6-26</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>6.53</theoretical-pi>
        <molecular-weight>93635.545</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="83333">Escherichia coli (strain K12)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X02164</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>581194</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P02918</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PBPA_ECOLI</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>PBP-1a</synonym>
          <synonym>ponA</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001173|Penicillin-binding protein 1A
MKFVKYFLILAVCCILLGAGSIYGLYRYIEPQLPDVATLKDVRLQIPMQIYSADGELIAQ
YGEKRRIPVTLDQIPPEMVKAFIATEDSRFYEHHGVDPVGIFRAASVALFSGHASQGAST
ITQQLARNFFLSPERTLMRKIKEVFLAIRIEQLLTKDEILELYLNKIYLGYRAYGVGAAA
QVYFGKTVDQLTLNEMAVIAGLPKAPSTFNPLYSMDRAVARRNVVLSRMLDEGYITQQQF
DQTRTEAINANYHAPEIAFSAPYLSEMVRQEMYNRYGESAYEDGYRIYTTITRKVQQAAQ
QAVRNNVLDYDMRHGYRGPANVLWKVGESAWDNNKITDTLKALPTYGPLLPAAVTSANPQ
QATAMLADGSTVALSMEGVRWARPYRSDTQQGPTPRKVTDVLQTGQQIWVRQVGDAWWLA
QVPEVNSALVSINPQNGAVMALVGGFDFNQSKFNRATQALRQVGSNIKPFLYTAAMDKGL
TLASMLNDVPISRWDASAGSDWQPKNSPPQYAGPIRLRQGLGQSKNVVMVRAMRAMGVDY
AAEYLQRFGFPAQNIVHTESLALGSASFTPMQVARGYAVMANGGFLVDPWFISKIENDQG
GVIFEAKPKVACPECDIPVIYGDTQKSNVLENNDVEDVAISREQQNVSVPMPQLEQANQA
LVAKTGAQEYAPHVINTPLAFLIKSALNTNIFGEPGWQGTGWRAGRDLQRRDIGGKTGTT
NSSKDAWFSGYGPGVVTSVWIGFDDHRRNLGHTTASGAIKDQISGYEGGAKSAQPAWDAY
MKAVLEGVPEQPLTPPPGIVTVNIDRSTGQLANGGNSREEYFIEGTQPTQQAVHEVGTTI
IDNGEAQELF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020469|Penicillin-binding protein 1A (mrcA)
GTGAAGTTCGTAAAGTATTTTTTGATCCTTGCAGTCTGTTGCATTCTGCTGGGAGCAGGC
TCGATTTATGGCCTATACCGCTACATCGAGCCACAACTGCCGGATGTGGCGACATTAAAA
GATGTTCGCCTGCAAATTCCGATGCAGATTTACAGCGCCGATGGCGAGCTGATTGCTCAA
TACGGTGAGAAACGTCGTATTCCGGTTACGTTGGATCAAATCCCACCGGAGATGGTGAAA
GCCTTTATCGCGACAGAAGACAGCCGCTTCTACGAGCATCACGGCGTTGACCCGGTGGGG
ATCTTCCGTGCAGCAAGCGTGGCGCTGTTCTCCGGTCACGCGTCACAAGGGGCAAGTACC
ATTACCCAGCAGCTGGCGAGAAACTTCTTCCTCAGTCCAGAACGCACGCTGATGCGTAAG
ATTAAGGAAGTCTTCCTCGCGATTCGCATTGAACAGCTGCTGACGAAAGACGAGATCCTC
GAGCTTTATCTGAACAAGATTTACCTTGGTTACCGCGCCTATGGTGTCGGTGCTGCGGCA
CAAGTCTATTTCGGAAAAACGGTCGACCAACTGACGCTGAACGAAATGGCGGTGATAGCC
GGGCTGCCGAAAGCGCCTTCCACCTTCAACCCGCTCTACTCGATGGATCGTGCCGTCGCG
CGGCGTAACGTCGTGCTGTCGCGGATGCTGGATGAAGGGTATATCACCCAACAACAGTTC
GATCAGACACGCACTGAGGCGATTAACGCTAACTATCACGCGCCGGAGATTGCTTTCTCT
GCGCCGTACCTGAGCGAAATGGTGCGCCAGGAGATGTATAACCGTTATGGCGAAAGTGCC
TATGAAGACGGTTATCGCATTTACACCACCATCACCCGCAAAGTGCAGCAGGCCGCGCAG
CAGGCGGTACGTAATAACGTGCTGGACTACGACATGCGCCACGGCTATCGCGGCCCGGCA
AATGTGCTGTGGAAAGTGGGCGAGTCGGCGTGGGATAACAACAAGATTACCGATACGCTG
AAGGCGCTGCCAACCTATGGTCCGCTGCTGCCTGCCGCAGTCACCAGCGCCAATCCTCAG
CAAGCGACGGCGATGCTGGCGGACGGGTCGACCGTCGCATTGAGTATGGAAGGCGTTCGC
TGGGCGCGTCCTTACCGTTCGGATACTCAGCAAGGACCGACGCCGCGTAAAGTGACCGAT
GTTCTGCAAACGGGTCAGCAAATCTGGGTTCGTCAGGTTGGCGATGCATGGTGGCTGGCA
CAAGTGCCGGAAGTGAACTCGGCGCTGGTGTCGATCAATCCGCAAAACGGTGCCGTTATG
GCGCTGGTCGGTGGCTTTGATTTCAATCAGAGCAAGTTTAACCGCGCCACCCAGGCACTG
CGTCAGGTGGGTTCCAACATCAAACCGTTCCTCTACACCGCGGCGATGGATAAAGGTCTG
ACGCTGGCAAGTATGTTGAACGATGTGCCAATTTCTCGCTGGGATGCAAGTGCCGGTTCT
GACTGGCAGCCGAAGAACTCACCACCGCAGTATGCTGGTCCAATTCGCTTACGTCAGGGG
CTGGGTCAGTCGAAAAACGTGGTGATGGTACGCGCAATGCGGGCGATGGGCGTCGACTAC
GCTGCAGAATATCTGCAACGCTTCGGCTTCCCGGCACAAAACATTGTCCACACCGAATCG
CTGGCGCTGGGTTCAGCGTCCTTCACCCCAATGCAGGTGGCGCGCGGCTACGCGGTCATG
GCGAACGGCGGCTTCCTGGTGGACCCGTGGTTTATCAGCAAAATTGAAAACGATCAGGGC
GGCGTGATTTTCGAAGCGAAACCGAAAGTAGCCTGCCCGGAATGCGATATTCCGGTGATT
TACGGTGATACGCAGAAATCGAACGTGCTGGAAAATAACGATGTTGAAGATGTCGCTATC
TCCCGCGAGCAGCAGAATGTTTCTGTACCAATGCCGCAGCTGGAGCAGGCAAATCAGGCG
TTAGTGGCGAAGACTGGCGCGCAGGAGTACGCACCGCACGTCATCAACACTCCGCTGGCA
TTCCTGATTAAGAGTGCTTTGAACACCAATATCTTTGGTGAGCCAGGCTGGCAGGGTACT
GGCTGGCGTGCAGGTCGTGATTTGCAGCGTCGCGATATCGGCGGGAAAACCGGGACCACT
AACAGTTCGAAAGATGCGTGGTTCTCGGGTTACGGTCCGGGCGTTGTGACCTCGGTCTGG
ATTGGCTTTGATGATCACCGTCGTAATCTCGGTCATACAACGGCTTCCGGAGCGATTAAA
GATCAGATCTCAGGTTACGAAGGCGGTGCCAAGAGTGCCCAGCCTGCATGGGACGCTTAT
ATGAAAGCCGTTCTTGAAGGTGTGCCGGAGCAGCCGCTGACGCCGCCACCGGGTATTGTG
ACGGTGAATATCGATCGCAGCACCGGGCAGTTAGCTAATGGTGGCAACAGCCGCGAAGAG
TATTTCATCGAAGGTACGCAGCCGACACAACAGGCAGTGCACGAGGTGGGAACGACCATT
ATCGATAATGGCGAGGCACAGGAATTGTTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00905</identifier>
            <name>Transpeptidase</name>
          </pfam>
          <pfam>
            <identifier>PF00912</identifier>
            <name>Transgly</name>
          </pfam>
          <pfam>
            <identifier>PF17092</identifier>
            <name>PCB_OB</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>penicillin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptidoglycan glycosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type D-Ala-D-Ala carboxypeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell wall organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidoglycan biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell shape</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="4">
      <id>BE0000790</id>
      <name>Penicillin-binding protein 3</name>
      <organism>Bacillus subtilis (strain 168)</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15388</ref-id>
            <pubmed-id>18076336</pubmed-id>
            <citation>Nicolau DP: Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother. 2008 Jan;9(1):23-37.</citation>
          </article>
          <article>
            <ref-id>A15389</ref-id>
            <pubmed-id>17488146</pubmed-id>
            <citation>Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA: Comparative review of the carbapenems. Drugs. 2007;67(7):1027-52.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P42971" source="Swiss-Prot">
        <name>Penicillin-binding protein 3</name>
        <general-function>Penicillin binding</general-function>
        <specific-function/>
        <gene-name>pbpC</gene-name>
        <locus/>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>7-23</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>6.56</theoretical-pi>
        <molecular-weight>74405.915</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="224308">Bacillus subtilis (strain 168)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>D38161</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>790944</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P42971</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PBPC_BACSU</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>PBP 3</synonym>
          <synonym>Penicillin-binding protein C</synonym>
          <synonym>PSPB20</synonym>
          <synonym>ycsM</synonym>
          <synonym>yzsA</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010557|Penicillin-binding protein 3
MLKKCILLVFLCVGLIGLIGCSKTDSPEDRMEAFVKQWNDQQFDDMYQSLTKDVKKEISK
KDFVNRYKAIYEQAGVKNLKVTAGEVDKDDQDNKTMKHIPYKVSMNTNAGKVSFKNTAVL
KLEKTDDEESWNIDWDPSFIFKQLADDKTVQIMSIEPKRGQIYDKNGKGLAVNTDVPEIG
IVPGELGDKKEKVIKELAKKLDLTEDDIKKKLDQGWVKDDSFVPLKKVKPDQEKLVSEAT
SLQGVTRTNVSSRYYPYGEKTAHLTGYVRAITAEELKKKKEGTYSDTSNIGIAGLENVYE
DKLRGTTGWKIYVPQTGEVIAEKKAKDGEDLHLTIDIKTQMKLYDELKDDSGAAVALQPK
TGETLALVSAPSYDPNGFIFGWSDKEWKKLNKDKNNPFSAKFNKTYAPGSTIKPIAAAIG
IKNGTLKADEKKTIKGKEWQKDSSWGGYSVTRVSERLQQVDLENALITSDNIYFAQNALD
MGADTFTKGLKTFGFSEDVPYEFPIQKSSIANDKLDSDILLADTGYGQGQMQMSPLHLAT
AYTPFVDNGDLVKPTLIKKDSQTADVWHKQVVTKEGAADITKGLKGVVEDERGSAYQPVV
KGITVAGKTGTAELKTSKDDKDGTENGWFVGYDYENKDLLVAMMIQNVQDRGGSHYVVEK
AKKQFQSN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010558|Penicillin-binding protein 3 (pbpC)
ATGTTAAAAAAGTGTATTCTACTAGTATTTCTATGCGTCGGATTGATTGGGTTAATCGGA
TGCTCCAAAACAGATTCACCAGAGGATCGCATGGAAGCATTCGTGAAACAGTGGAACGAT
CAGCAATTCGATGACATGTATCAAAGCCTGACTAAAGATGTCAAAAAAGAAATCTCCAAA
AAAGATTTCGTCAACAGGTATAAAGCCATCTATGAGCAGGCCGGCGTAAAAAATTTGAAA
GTCACTGCGGGAGAAGTAGATAAGGACGATCAAGACAACAAGACGATGAAACATATCCCG
TATAAAGTCAGCATGAACACAAATGCCGGCAAAGTCAGCTTCAAGAATACTGCTGTGCTG
AAATTAGAAAAAACAGATGACGAGGAGTCATGGAATATAGATTGGGACCCATCGTTTATT
TTCAAGCAGCTGGCTGACGACAAAACCGTGCAAATTATGAGCATTGAACCGAAACGAGGC
CAAATTTACGATAAAAATGGAAAAGGCTTAGCCGTCAATACAGATGTTCCGGAAATTGGA
ATTGTTCCCGGAGAGCTTGGCGATAAAAAAGAGAAAGTCATAAAAGAACTCGCCAAAAAA
CTTGATTTGACTGAAGACGACATCAAGAAAAAGCTGGATCAAGGCTGGGTAAAAGACGAT
TCGTTTGTGCCGCTCAAAAAGGTCAAGCCTGACCAGGAGAAATTAGTTTCTGAAGCGACG
TCATTACAAGGCGTAACAAGAACGAATGTCAGCTCCCGCTACTATCCGTATGGCGAAAAG
ACAGCCCATTTGACAGGCTATGTCCGCGCCATTACAGCGGAAGAACTGAAGAAAAAGAAA
GAAGGAACGTACAGCGATACGTCTAACATCGGTATCGCCGGACTTGAAAATGTGTATGAA
GACAAGCTAAGAGGCACAACTGGCTGGAAAATCTACGTGCCGCAAACCGGGGAAGTCATC
GCTGAAAAGAAAGCAAAGGACGGCGAGGATCTTCACCTCACAATTGATATCAAAACGCAA
ATGAAGCTGTATGATGAACTGAAGGATGACAGCGGGGCGGCAGTCGCGCTGCAGCCGAAG
ACAGGCGAAACACTCGCCCTTGTCAGCGCGCCTTCCTACGATCCAAACGGATTTATTTTC
GGCTGGAGCGATAAGGAATGGAAAAAGCTAAACAAAGATAAAAACAATCCGTTTTCAGCG
AAATTCAATAAGACATACGCGCCAGGTTCTACCATTAAACCGATTGCGGCTGCTATTGGA
ATCAAAAACGGCACCCTTAAAGCCGATGAGAAGAAAACAATCAAAGGCAAGGAGTGGCAA
AAAGATTCAAGCTGGGGCGGCTATTCAGTGACACGTGTGTCTGAGAGACTTCAACAAGTC
GATTTGGAAAACGCCCTTATTACGTCAGACAATATTTATTTTGCCCAGAATGCGCTTGAT
ATGGGAGCGGACACCTTTACAAAAGGCTTGAAGACATTCGGTTTTTCAGAGGACGTTCCG
TACGAATTCCCGATCCAGAAATCGTCTATTGCAAATGACAAGCTTGATTCAGACATTTTG
CTTGCGGATACAGGCTACGGACAAGGGCAAATGCAAATGTCTCCGCTTCACTTGGCAACT
GCTTACACGCCATTTGTTGACAATGGAGACCTTGTCAAACCGACGCTGATCAAAAAAGAT
TCACAAACAGCTGATGTTTGGCACAAGCAAGTGGTCACGAAGGAAGGAGCGGCAGACATT
ACAAAAGGTCTGAAAGGCGTTGTGGAAGATGAGCGCGGATCAGCGTATCAGCCTGTCGTG
AAAGGAATCACAGTGGCTGGAAAAACAGGAACAGCCGAGCTGAAAACATCAAAAGATGAT
AAAGACGGCACGGAAAATGGCTGGTTTGTCGGCTACGATTACGAAAACAAAGACCTGCTT
GTCGCCATGATGATCCAAAATGTGCAGGACCGCGGCGGCAGCCACTATGTCGTTGAGAAA
GCGAAAAAGCAATTTCAATCGAATTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF03717</identifier>
            <name>PBP_dimer</name>
          </pfam>
          <pfam>
            <identifier>PF00905</identifier>
            <name>Transpeptidase</name>
          </pfam>
          <pfam>
            <identifier>PF05223</identifier>
            <name>MecA_N</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>penicillin binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell wall organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidoglycan biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell shape</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="5">
      <id>BE0008485</id>
      <name>Penicillin-binding protein 4</name>
      <organism>Staphylococcus aureus</organism>
      <actions/>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L7526</ref-id>
            <title>FDA: Primaxin Label</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050587s081lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P72355" source="TrEMBL">
        <name>Penicillin-binding protein 4</name>
        <general-function>Serine-type d-ala-d-ala carboxypeptidase activity</general-function>
        <specific-function/>
        <gene-name>pbp4</gene-name>
        <locus/>
        <cellular-location/>
        <transmembrane-regions>402-423</transmembrane-regions>
        <signal-regions>1-24</signal-regions>
        <theoretical-pi/>
        <molecular-weight>48237.14</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="1280">Staphylococcus aureus</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P72355</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>P72355_STAAU</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0022409|Penicillin-binding protein 4
MKNLISIIIILCLTLSIMTPYAQATNSDVTPVQAANQYGYAGLSAAYEPTSAVNVSQTGQ
LLYQYNIDTKWNPASMTKLMTMYLTLEAVNKGQLSLDDTVTMTNKEYIMSTLPELSNTKL
YPGQVWTIADLLQITVSNSSNAAALILAKKVSKNTSDFVDLMNNKAKAIGMKNTHFVNPT
GAENSRLRTFAPTKYKDQERTVTTARDYAILDLHVIKETPKILDFTKQLAPTTLAVTYYT
FNFSLEGAKMSLPGTDGLKTGSSDTANYNHTITTKRGKFRINQVIMGAGDYKNLGGEKQR
NMMGNALMERSFDQYKYVKILSKGEQRINGKKYYVENDLYDVLPSDFSKKDYKLVVEDGK
VHADYPREFINKDYGPPTVEVHQPIIQKANTVAKSMWEEHPLFTIIGGTCLVAGLALIVH
MIINRLFRKRK</amino-acid-sequence>
        <gene-sequence format="FASTA"/>
        <pfams>
          <pfam>
            <identifier>PF00768</identifier>
            <name>Peptidase_S11</name>
          </pfam>
          <pfam>
            <identifier>PF09211</identifier>
            <name>DUF1958</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type D-Ala-D-Ala carboxypeptidase activity</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="6">
      <id>BE0001148</id>
      <name>Dipeptidase 1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L7568</ref-id>
            <title>FDA: Recarbrio Label</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P16444" source="Swiss-Prot">
        <name>Dipeptidase 1</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Hydrolyzes a wide range of dipeptides. Implicated in the renal metabolism of glutathione and its conjugates. Converts leukotriene D4 to leukotriene E4; it may play an important role in the regulation of leukotriene activity.</specific-function>
        <gene-name>DPEP1</gene-name>
        <locus>16q24.3</locus>
        <cellular-location>Apical cell membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-16</signal-regions>
        <theoretical-pi>6.09</theoretical-pi>
        <molecular-weight>45673.48</molecular-weight>
        <chromosome-location>16</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3002</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>DPEP1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>D13137</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>219600</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P16444</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DPEP1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.13.19</synonym>
          <synonym>Dehydropeptidase-I</synonym>
          <synonym>hRDP</synonym>
          <synonym>MDP</synonym>
          <synonym>Microsomal dipeptidase</synonym>
          <synonym>RDP</synonym>
          <synonym>Renal dipeptidase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010801|Dipeptidase 1
MWSGWWLWPLVAVCTADFFRDEAERIMRDSPVIDGHNDLPWQLLDMFNNRLQDERANLTT
LAGTHTNIPKLRAGFVGGQFWSVYTPCDTQNKDAVRRTLEQMDVVHRMCRMYPETFLYVT
SSAGIRQAFREGKVASLIGVEGGHSIDSSLGVLRALYQLGMRYLTLTHSCNTPWADNWLV
DTGDSEPQSQGLSPFGQRVVKELNRLGVLIDLAHVSVATMKATLQLSRAPVIFSHSSAYS
VCASRRNVPDDVLRLVKQTDSLVMVNFYNNYISCTNKANLSQVADHLDHIKEVAGARAVG
FGGDFDGVPRVPEGLEDVSKYPDLIAELLRRNWTEAEVKGALADNLLRVFEAVEQASNLT
QAPEEEPIPLDQLGGSCRTHYGYSSGASSLHRHWGLLLASLAPLVLCLSLL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010802|Dipeptidase 1 (DPEP1)
ATGTGGAGCGGATGGTGGCTGTGGCCCCTTGTGGCCGTCTGCACTGCAGACTTCTTTCGG
GACGAGGCAGAGAGGATCATGAGGGACTCCCCTGTCATTGATGGGCACAATGACCTCCCC
TGGCAGCTGCTGGATATGTTCAACAACCGGCTGCAGGACGAGAGGGCCAACCTGACCACC
TTGGCCGGCACACACACCAACATCCCCAAGCTGAGGGCCGGCTTTGTGGGAGGCCAGTTC
TGGTCCGTGTACACGCCCTGCGACACCCAGAACAAAGACGCCGTGCGGAGGACGCTGGAG
CAGATGGACGTGGTCCACCGCATGTGCCGGATGTACCCGGAGACCTTCCTGTATGTCACC
AGCAGTGCAGGCATTCGGCAGGCCTTCCGGGAAGGGAAGGTGGCCAGCCTGATCGGCGTG
GAGGGCGGCCACTCCATTGACAGCAGTTTGGGCGTCCTGCGGGCACTCTATCAGCTGGGC
ATGCGGTACCTGACCCTCACCCACAGCTGCAACACGCCCTGGGCTGACAACTGGCTGGTG
GACACGGGAGACAGCGAGCCCCAGAGCCAAGGCTTGTCACCCTTTGGGCAGCGTGTGGTG
AAGGAGCTGAACCGTCTGGGGGTCCTCATCGACTTGGCTCACGTGTCTGTGGCCACCATG
AAGGCCACCCTGCAGCTGTCCAGAGCCCCGGTCATCTTCAGCCACTCCTCGGCCTACAGC
GTGTGCGCAAGCCGGCGCAACGTGCCTGACGACGTCCTGAGGCTGGTGAAACAGACAGAC
AGCCTGGTGATGGTGAACTTCTACAACAATTACATTTCCTGCACCAACAAGGCCAACCTG
TCCCAAGTGGCCGACCATCTGGATCACATCAAGGAGGTGGCAGGAGCCAGAGCCGTGGGT
TTTGGTGGGGACTTTGATGGTGTTCCAAGGGTCCCTGAGGGGCTGGAGGACGTCTCCAAG
TATCCAGACCTGATCGCTGAGCTGCTCAGGAGGAACTGGACGGAGGCGGAGGTCAAGGGC
GCACTGGCTGACAACCTGCTGAGGGTCTTCGAGGCTGTGGAACAGGCCAGCAACCTCACA
CAGGCTCCCGAGGAGGAGCCCATCCCGCTGGACCAGCTGGGTGGCTCCTGCAGGACCCAT
TACGGCTACTCCTCTGGGGCTTCCAGCCTCCATCGCCACTGGGGGCTCCTGCTGGCCTCC
CTCGCTCCCCTGGTCCTCTGTCTGTCTCTCCTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01244</identifier>
            <name>Peptidase_M19</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>anchored component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>apical part of cell</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>microvillus membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cysteine-type endopeptidase inhibitor activity involved in apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dipeptidyl-peptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GPI anchor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metallodipeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metalloexopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>modified amino acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>antibiotic metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular lactam catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to calcium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to nitric oxide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glutathione metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>homocysteine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukotriene metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cysteine-type endopeptidase activity involved in apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="7">
      <id>BE0002015</id>
      <name>Beta-lactamase SHV-1</name>
      <organism>Escherichia coli</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L7568</ref-id>
            <title>FDA: Recarbrio Label</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P0AD63" source="Swiss-Prot">
        <name>Beta-lactamase SHV-1</name>
        <general-function>Beta-lactamase activity</general-function>
        <specific-function/>
        <gene-name>bla</gene-name>
        <locus/>
        <cellular-location>Cytoplasmic</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-21</signal-regions>
        <theoretical-pi>8.08</theoretical-pi>
        <molecular-weight>31223.635</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="562">Escherichia coli</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF148850</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>5002312</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P0AD63</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>BLA1_ECOLX</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.5.2.6</synonym>
          <synonym>PIT-2</synonym>
          <synonym>shv1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021982|Beta-lactamase SHV-1
MRYIRLCIISLLATLPLAVHASPQPLEQIKLSESQLSGRVGMIEMDLASGRTLTAWRADE
RFPMMSTFKVVLCGAVLARVDAGDEQLERKIHYRQQDLVDYSPVSEKHLADGMTVGELCA
AAITMSDNSAANLLLATVGGPAGLTAFLRQIGDNVTRLDRWETELNEALPGDARDTTTPA
SMAATLRKLLTSQRLSARSQRQLLQWMVDDRVAGPLIRSVLPAGWFIADKTGAGERGARG
IVALLGPNNKAERIVVIYLRDTPASMAERNQQIAGIGAALIEHWQR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0003988|861 bp
ATGCGTTATATTCGCCTGTGTATTATCTCCCTGTTAGCCACCCTGCCGCTGGCGGTACAC
GCCAGCCCGCAGCCGCTTGAGCAAATTAAACTAAGCGAAAGCCAGCTGTCGGGCCGCGTA
GGCATGATAGAAATGGATCTGGCCAGCGGCCGCACGCTGACCGCCTGGCGCGCCGATGAA
CGCTTTCCCATGATGAGCACCTTTAAAGTAGTGCTCTGCGGCGCAGTGCTGGCGCGGGTG
GATGCCGGTGACGAACAGCTGGAGCGAAAGATCCACTATCGCCAGCAGGATCTGGTGGAC
TACTCGCCGGTCAGCGAAAAACACCTTGCCGACGGCATGACGGTCGGCGAACTCTGCGCC
GCCGCCATTACCATGAGCGATAACAGCGCCGCCAATCTGCTACTGGCCACCGTCGGCGGC
CCCGCAGGATTGACTGCCTTTTTGCGCCAGATCGGCGACAACGTCACCCGCCTTGACCGC
TGGGAAACGGAACTGAATGAGGCGCTTCCCGGCGACGCCCGCGACACCACTACCCCGGCC
AGCATGGCCGCGACCCTGCGCAAGCTGCTGACCAGCCAGCGTCTGAGCGCCCGTTCGCAA
CGGCAGCTGCTGCAGTGGATGGTGGACGATCGGGTCGCCGGACCGTTGATCCGCTCCGTG
CTGCCGGCGGGCTGGTTTATCGCCGATAAGACCGGAGCTGGCGAGCGGGGTGCGCGCGGG
ATTGTCGCCCTGCTTGGCCCGAATAACAAAGCAGAGCGCATTGTGGTGATTTATCTGCGG
GATACCCCGGCGAGCATGGCCGAGCGAAATCAGCAAATCGCCGGGATCGGCGCGGCGCTG
ATCGAGCACTGGCAACGCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00144</identifier>
            <name>Beta-lactamase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>function</category>
            <description>beta-lactamase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>beta-lactam antibiotic catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="8">
      <id>BE0003894</id>
      <name>Beta-lactamase TEM</name>
      <organism>Escherichia coli</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L7568</ref-id>
            <title>FDA: Recarbrio Label</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P62593" source="Swiss-Prot">
        <name>Beta-lactamase TEM</name>
        <general-function>TEM-type are the most prevalent beta-lactamases in enterobacteria; they hydrolyze the beta-lactam bond in susceptible beta-lactam antibiotics, thus conferring resistance to penicillins and cephalosporins. TEM-3 and TEM-4 are capable of hydrolyzing cefotaxime and ceftazidime. TEM-5 is capable of hydrolyzing ceftazidime. TEM-6 is capable of hydrolyzing ceftazidime and aztreonam. TEM-8/CAZ-2, TEM-16/CAZ-7 and TEM-24/CAZ-6 are markedly active against ceftazidime. IRT-4 shows resistance to beta-lactamase inhibitors.</general-function>
        <specific-function>Beta-lactamase activity</specific-function>
        <gene-name>bla</gene-name>
        <locus/>
        <cellular-location>Cytoplasmic</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-23</signal-regions>
        <theoretical-pi>5.92</theoretical-pi>
        <molecular-weight>31514.865</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="562">Escherichia coli</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J01749</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>208959</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P62593</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>BLAT_ECOLX</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.5.2.6</synonym>
          <synonym>IRT-4</synonym>
          <synonym>Penicillinase</synonym>
          <synonym>TEM-1</synonym>
          <synonym>TEM-16/CAZ-7</synonym>
          <synonym>TEM-2</synonym>
          <synonym>TEM-24/CAZ-6</synonym>
          <synonym>TEM-3</synonym>
          <synonym>TEM-4</synonym>
          <synonym>TEM-5</synonym>
          <synonym>TEM-6</synonym>
          <synonym>TEM-8/CAZ-2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0022085|Beta-lactamase TEM
MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGYIELDLNSGKILESFRP
EERFPMMSTFKVLLCGAVLSRVDAGQEQLGRRIHYSQNDLVEYSPVTEKHLTDGMTVREL
CSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRLDRWEPELNEAIPNDERDTTM
PAAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPLLRSALPAGWFIADKSGAGERGS
RGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIAEIGASLIKHW</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0007458|1191 bp
ATGAAATCTAACAATGCGCTCATCGTCATCCTCGGCACCGTCACCCTGGATGCTGTAGGC
ATAGGCTTGGTTATGCCGGTACTGCCGGGCCTCTTGCGGGATATCGTCCATTCCGACAGC
ATCGCCAGTCACTATGGCGTGCTGCTAGCGCTATATGCGTTGATGCAATTTCTATGCGCA
CCCGTTCTCGGAGCACTGTCCGACCGCTTTGGCCGCCGCCCAGTCCTGCTCGCTTCGCTA
CTTGGAGCCACTATCGACTACGCGATCATGGCGACCACACCCGTCCTGTGGATCCTCTAC
GCCGGACGCATCGTGGCCGGCATCACCGGCGCCACAGGTGCGGTTGCTGGCGCCTATATC
GCCGACATCACCGATGGGGAAGATCGGGCTCGCCACTTCGGGCTCATGAGCGCTTGTTTC
GGCGTGGGTATGGTGGCAGGCCCCGTGGCCGGGGGACTGTTGGGCGCCATCTCCTTGCAT
GCACCATTCCTTGCGGCGGCGGTGCTCAACGGCCTCAACCTACTACTGGGCTGCTTCCTA
ATGCAGGAGTCGCATAAGGGAGAGCGTCGACCGATGCCCTTGAGAGCCTTCAACCCAGTC
AGCTCCTTCCGGTGGGCGCGGGGCATGACTATCGTCGCCGCACTTATGACTGTCTTCTTT
ATCATGCAACTCGTAGGACAGGTGCCGGCAGCGCTCTGGGTCATTTTCGGCGAGGACCGC
TTTCGCTGGAGCGCGACGATGATCGGCCTGTCGCTTGCGGTATTCGGAATCTTGCACGCC
CTCGCTCAAGCCTTCGTCACTGGTCCCGCCACCAAACGTTTCGGCGAGAAGCAGGCCATT
ATCGCCGGCATGGCGGCCGACGCGCTGGGCTACGTCTTGCTGGCGTTCGCGACGCGAGGC
TGGATGGCCTTCCCCATTATGATTCTTCTCGCTTCCGGCGGCATCGGGATGCCCGCGTTG
CAGGCCATGCTGTCCAGGCAGGTAGATGACGACCATCAGGGACAGCTTCAAGGATCGCTC
GCGGCTCTTACCAGCCTAACTTCGATCACTGGACCGCTGATCGTCACGGCGATTTATGCC
GCCTCGGCGAGCACATGGAACGGGTTGGCATGGATTGTAGGCGCCGCCCTATACCTTGTC
TGCCTCCCCGCGTTGCGTCGCGGTGCATGGAGCCGGGCCACCTCGACCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00144</identifier>
            <name>Beta-lactamase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>function</category>
            <description>beta-lactamase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>beta-lactam antibiotic catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="9">
      <id>BE0002831</id>
      <name>Beta-lactamase CTX-M</name>
      <organism>Escherichia coli</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L7568</ref-id>
            <title>FDA: Recarbrio Label</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="Q939N4" source="TrEMBL">
        <name>Beta-lactamase</name>
        <general-function/>
        <specific-function>Beta-lactamase activity</specific-function>
        <gene-name/>
        <locus/>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions>1-28</signal-regions>
        <theoretical-pi/>
        <molecular-weight>30893.0</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="562">Escherichia coli</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q939N4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>Q939N4_ECOLX</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.5.2.6</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0052131|Beta-lactamase
MVTKRVQRMMFAAAACIPLLLGSAPLYAQTSAVQQKLAALEKSSGGRLGVALIDTADNTQ
VLYRGDERFPMCSTSKVMAAAAVLKQSETQKQLLNQPVEIKPADLVNYNPIAEKHVNGTM
TLAELSAAALQYSDNTAMNKLIAQLGGPGGVTAFARAIGDETFRLDRTEPTLNTAIPGDP
RDTTTPRAMAQTLRQLTLGHALGETQRAQLVTWLKGNTTGAASIRAGLPTSWTAGDKTGS
GGYGTTNDIAVIWPQGRAPLVLVTYFTQPQQNAESRRDVLASAARIIAEGL</amino-acid-sequence>
        <gene-sequence format="FASTA"/>
        <pfams/>
        <go-classifiers>
          <go-classifier>
            <category>function</category>
            <description>beta-lactamase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>beta-lactam antibiotic catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q9L5C7" source="TrEMBL">
        <name>Beta-lactamase</name>
        <general-function/>
        <specific-function>Beta-lactamase activity</specific-function>
        <gene-name>blaCTX-M-14</gene-name>
        <locus/>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions>1-28</signal-regions>
        <theoretical-pi/>
        <molecular-weight>30979.09</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="562">Escherichia coli</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9L5C7</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>Q9L5C7_ECOLX</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.5.2.6</synonym>
          <synonym>beta-lactamase CTX-M-14</synonym>
          <synonym>bla-CTX-M-14a</synonym>
          <synonym>blaCTX-M</synonym>
          <synonym>blaCTX-M-14a</synonym>
          <synonym>blaCTX-M-14b</synonym>
          <synonym>blaCTX-M-14c</synonym>
          <synonym>blaCTX-M-27b</synonym>
          <synonym>blatoho-3</synonym>
          <synonym>blaUOE-2</synonym>
          <synonym>CTX-M-14</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0052132|Beta-lactamase
MVTKRVQRMMFAAAACIPLLLGSAPLYAQTSAVQQKLAALEKSSGGRLGVALIDTADNTQ
VLYRGDERFPMCSTSKVMAAAAVLKQSETQKQLLNQPVEIKPADLVNYNPIAEKHVNGTM
TLAELSAAALQYSDNTAMNKLIAQLGGPGGVTAFARAIGDETFRLDRTEPTLNTAIPGDP
RDTTTPRAMAQTLRQLTLGHALGETQRAQLVTWLKGNTTGAASIRAGLPTSWTVGDKTGS
GDYGTTNDIAVIWPQGRAPLVLVTYFTQPQQNAESRRDVLASAARIIAEGL</amino-acid-sequence>
        <gene-sequence format="FASTA"/>
        <pfams/>
        <go-classifiers>
          <go-classifier>
            <category>function</category>
            <description>beta-lactamase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>beta-lactam antibiotic catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q840M4" source="TrEMBL">
        <name>Beta-lactamase</name>
        <general-function/>
        <specific-function>Beta-lactamase activity</specific-function>
        <gene-name>blaCTX-M-27</gene-name>
        <locus/>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions>1-28</signal-regions>
        <theoretical-pi/>
        <molecular-weight>30921.06</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="562">Escherichia coli</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q840M4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>Q840M4_ECOLX</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.5.2.6</synonym>
          <synonym>CTX-M-27</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0052133|Beta-lactamase
MVTKRVQRMMFAAAACIPLLLGSAPLYAQTSAVQQKLAALEKSSGGRLGVALIDTADNTQ
VLYRGDERFPMCSTSKVMAAAAVLKQSETQKQLLNQPVEIKPADLVNYNPIAEKHVNGTM
TLAELSAAALQYSDNTAMNKLIAQLGGPGGVTAFARAIGDETFRLDRTEPTLNTAIPGDP
RDTTTPRAMAQTLRQLTLGHALGETQRAQLVTWLKGNTTGAASIRAGLPTSWTVGDKTGS
GGYGTTNDIAVIWPQGRAPLVLVTYFTQPQQNAESRRDVLASAARIIAEGL</amino-acid-sequence>
        <gene-sequence format="FASTA"/>
        <pfams/>
        <go-classifiers>
          <go-classifier>
            <category>function</category>
            <description>beta-lactamase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>beta-lactam antibiotic catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="10">
      <id>BE0009747</id>
      <name>Beta-lactamase (KPC-2)</name>
      <organism>Klebsiella pneumoniae</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A185330</ref-id>
            <pubmed-id>15206053</pubmed-id>
            <citation>Bradford PA, Bratu S, Urban C, Visalli M, Mariano N, Landman D, Rahal JJ, Brooks S, Cebular S, Quale J: Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis. 2004 Jul 1;39(1):55-60. doi: 10.1086/421495. Epub 2004 Jun 14.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L7568</ref-id>
            <title>FDA: Recarbrio Label</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q93LQ9" source="TrEMBL">
        <name>Beta-lactamase</name>
        <general-function/>
        <specific-function>Beta-lactamase activity</specific-function>
        <gene-name>KPC-2</gene-name>
        <locus/>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions>1-24</signal-regions>
        <theoretical-pi/>
        <molecular-weight>31114.99</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="573">Klebsiella pneumoniae</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q93LQ9</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>Q93LQ9_KLEPN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.5.2.6</synonym>
          <synonym>bla</synonym>
          <synonym>blaKPC</synonym>
          <synonym>blaKPC-2</synonym>
          <synonym>kpc2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0052114|Beta-lactamase
MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMDTGSGATVSYR
AEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNALVPWSPISEKYLTTGMTVAE
LSAAAVQYSDNAAANLLLKELGGPAGLTAFMRSIGDTTFRLDRWELELNSAIPGDARDTS
SPRAVTESLQKLTLGSALAAPQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVY
GTANDYAVVWPTGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ</amino-acid-sequence>
        <gene-sequence format="FASTA"/>
        <pfams/>
        <go-classifiers>
          <go-classifier>
            <category>function</category>
            <description>beta-lactamase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>beta-lactam antibiotic catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>